Comparative pharmacokinetics of some veterinary specialties including enrofloxacin in dogs

• Autorzy: Eraslan G. , Liman B.C. , Cam Y. , Kanbur M.
• Języki publikacji: EN

Abstrakty

EN

This study was aimed at the comparison of the pharmacokinetics of 4 different parenteral commercial specialties containing enrofloxacin as an active substance. For this purpose, 35 2-3-years-old, male mix-breed dogs were used. Five groups including 7 animals each were established. Each animal included in the first group (group 1) was intravenously administered a reference standard for enrofloxacin at a dose of 5 mg/kg body weight. Groups 2, 3, 4 and 5 were administered different parenteral preparations containing enrofloxacin at the same dose but intramuscularly. Subsequent to drug administration, blood samples were collected from all of the groups at 0.083, 0.25, 0.50, 1, 2, 4, 6, 12, 24, and 36 hours. The blood samples were centrifuged for the separation of sera. Enrofloxacin analyses in serum samples were performed by means of the spectrofluorometric method. Upon evaluation based on pharmacokinetic distribution and according to the findings obtained, a statistically significant difference was determined in other groups with respect to A₁, α, t1/2α, V₁ ve k₁₀ when compared to administration by route IV. This difference was demonstrated to be in the form of a decrease for A₁*, α and k₁₀, and increase for t1/2α and V₁, when compared to administration by route IV. Excluding t1/2α, statistically significant differences were not observed between all the commercial preparations (groups 2-5).

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2008
• Tom: 64
• Numer: 03
• Opis fizyczny: p.288-291,fig.,ref.

Twórcy

autor

Eraslan G.

• Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Erciyes, Kayseri, Turkey

autor

Liman B.C.

autor

Cam Y.

autor

Kanbur M.

Bibliografia

• 1.Altreuther P.: Data on chemistry and toxicology of Baytril®. Vet. Med. Rev. 1987, 59, 87-89.
• 2.Bauditz R.: Results of clinical studies with Baytril® in poultry. Vet. Med. Rev. 1987a, 59, 130-136.
• 3.Bauditz R.: Results of clinical studies with Baytril® in dog and cats. Vet. Med. Rev. 1987b, 59, 137-140.
• 4.Boothe D. M., Boeckh A., Boothe H. W., Wilkie S., Jones S.: Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. Vet. Ther. 2002, 3, 409-419.
• 5.Elmas M., Tras B., Kaya S., Bas A. L., Yazar E., Yarsan E.: Pharmacokinetics of enrofloxacin after intravenous and intramuscular administration in Angora goats. Can. J. Vet. Res. 2001, 65, 64-67.
• 6.Elmas M., Uney K., Yazar E., Karabacak A., Tras B.: Pharmacokinetics of enrofloxacin following intravenous and intramuscular administration in Angora rabbits. Res. Vet. Sci. 2007, 82, 242-245.
• 7.Frazier D. L., Thompson L., Trettien A., Evans E. I.: Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs. J. Vet. Pharmacol. Ther. 2000, 23, 293-302.
• 8.Rose K. M.: DNA topoisomerases as targets for chemotherapy. FASEB J. 1988, 2, 2492-2496.
• 9.Kaya S.: Kemoterapotikler, [in:] Uygulamali Veteriner Farmakoloji ve Ilacla Sagaltim Secenekleri. 2. Baskɩ. 2. Cilt. Medisan Yayinevi 2000, 267-440.
• 10.Kaya S., Baydan E., Bilgili A., Yarsan E., Seker Y.: Etlik piliclerde enrofloksasinin farmakokinetigi ve manganla enrofloksasin arasinda emilme yonunden etkilesme. Ankara Üniv. Vet. Fak. Derg. 1996, 43, 195-202.
• 11.Kung K., Wanner M.: Pharmacokinetics of Baytril (enrofloxacin) in dogs. Schweiz. Arch. Tierheilkd. 1994, 136, 329-334.
• 12.Lode H., Höffken G., Borner K., Koeppe P.: Unique aspects of quinolone pharmacokinetics. Clin. Pharmacokinet. 1989, 16, 1-4.
• 13.Ogino T., Mizuno Y., Ogata T., Takahashi Y.: Pharmacokinetic interactions of flunixin meglumine and enrofloxacin in dogs. Am. J. Vet. Res. 2005, 66, 1209-1213.
• 14.Prescott J. F., Yielding K. M.: In vitro susceptibilty of selected veterinary bacterial patogens to ciprofloxacin, enrofloxacin and norfloxacin. Can. J. Vet. Res. 1990, 54, 195-197.
• 15.Rizk M., Belal F., Ibrahim F., Ahmed S., El-Enany N.: Spectroflorimetric analysis of certain 4-quinolone pharmaceuticals and biological fluids. Pharm. Acta. Helv. 2000, 74, 371-377.
• 16.Shumaker R. C.: PKCALC. A basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug. Metabol. Rev. 1986, 17, 331-348.
• 17.Sorgel F., Kinzig M.: Pharmacokinetics of gyrase inhibitors, part 1: Basic chemistry and gastrointestinal disposition. Am. J. Med. 1993, 94, 44-55.
• 18.Spoo J. W., Riviere J. E.: Chloramphenicol, macrolides, lincosamides, fluoroquinolones, and micellaneus antibiotic, [in:] Adams H. R. (ed.): Veterinary Pharmacology and Therapeutics. Iowa State University Pres 1995, 820-855.
• 19.Stein G. E.: The 4-quinolone antibiotics: Past, present, and future. Pharmacotherapy 1988, 8, 301-314.
• 20.Sumano L. H., Ocampo C. L., Gutiérrez O. L.: Non-bioequivalence of various trademarks of enrofloxacin and Baytril in cows. Dtsch. Tierärztl. Wochenschr. 2001, 108, 311-314.
• 21.Sumano L. H., Gutierrez O. L., Zamora M. A.: Boequivalence of four preparations of enrofloxacin in poultry. J. Vet. Pharmacol. Ther. 2001, 24, 309-313.
• 22.Vancutsem P. M., Babish J. G., Schwark W. S.: The Fluoroquinolone antimicrobials: structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell. Vet. 1989, 80, 173-186.
• 23.Wagner J. G.: Fundamentals of clinical pharmacokinetics. Chicago: Drug Intelligence Pub Inc. 1st Ed., Hamilton Press, IL, USA 1975, 57-128.
• 24.Wolfson J. S., Hooper D. C.: The Floroquinolones: structures, mechanism of action and resistance, and spectra of activity in vitro. Antimicrob. Agents Chemother. 1985, 28, 581-586.

Uwagi

Rekord w opracowaniu